151 related articles for article (PubMed ID: 25695234)
1. Nuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomas.
Assi J; Srivastava G; Matta A; MacMillan C; Ralhan R; Walfish PG
PLoS One; 2015; 10(2):e0107586. PubMed ID: 25695234
[TBL] [Abstract][Full Text] [Related]
2. An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.
He HC; Kashat L; Kak I; Kunavisarut T; Gundelach R; Kim D; So AK; MacMillan C; Freeman JL; Ralhan R; Walfish PG
PLoS One; 2012; 7(9):e42893. PubMed ID: 23049733
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma.
Kunavisarut T; Kak I; Macmillan C; Ralhan R; Walfish PG
BMC Cancer; 2012 Nov; 12():523. PubMed ID: 23153310
[TBL] [Abstract][Full Text] [Related]
4. Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients.
Srivastava G; Assi J; Kashat L; Matta A; Chang M; Walfish PG; Ralhan R
BMC Cancer; 2014 Sep; 14():726. PubMed ID: 25265904
[TBL] [Abstract][Full Text] [Related]
5. EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis.
Ralhan R; Cao J; Lim T; Macmillan C; Freeman JL; Walfish PG
BMC Cancer; 2010 Jun; 10():331. PubMed ID: 20579375
[TBL] [Abstract][Full Text] [Related]
6. Subcellular differential expression of Ep-ICD in oral dysplasia and cancer is associated with disease progression and prognosis.
Somasundaram RT; Kaur J; Leong I; MacMillan C; Witterick IJ; Walfish PG; Ralhan R
BMC Cancer; 2016 Jul; 16():486. PubMed ID: 27421772
[TBL] [Abstract][Full Text] [Related]
7. Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers.
Ralhan R; He HC; So AK; Tripathi SC; Kumar M; Hasan MR; Kaur J; Kashat L; MacMillan C; Chauhan SS; Freeman JL; Walfish PG
PLoS One; 2010 Nov; 5(11):e14130. PubMed ID: 21152431
[TBL] [Abstract][Full Text] [Related]
8. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
9. STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma.
Ihlaseh-Catalano SM; Drigo SA; de Jesus CM; Domingues MA; Trindade Filho JC; de Camargo JL; Rogatto SR
Histopathology; 2013 Nov; 63(5):678-85. PubMed ID: 24025158
[TBL] [Abstract][Full Text] [Related]
10. Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer.
Fong D; Moser P; Kasal A; Seeber A; Gastl G; Martowicz A; Wurm M; Mian C; Obrist P; Mazzoleni G; Spizzo G
Histopathology; 2014 Apr; 64(5):683-92. PubMed ID: 24117877
[TBL] [Abstract][Full Text] [Related]
11. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.
Horvath LG; Henshall SM; Lee CS; Kench JG; Golovsky D; Brenner PC; O'Neill GF; Kooner R; Stricker PD; Grygiel JJ; Sutherland RL
Int J Cancer; 2005 Jan; 113(3):415-22. PubMed ID: 15455387
[TBL] [Abstract][Full Text] [Related]
12. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
Abd El-Maqsoud NM; Osman NA; Abd El-Hamid AM; Fath El-Bab TK; Galal EM
Clin Genitourin Cancer; 2016 Apr; 14(2):e143-52. PubMed ID: 26794392
[TBL] [Abstract][Full Text] [Related]
13. SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
Bauman TM; Becka AJ; Sehgal PD; Huang W; Ricke WA
Hum Pathol; 2015 Nov; 46(11):1744-51. PubMed ID: 26344417
[TBL] [Abstract][Full Text] [Related]
14. Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis.
Warneke VS; Behrens HM; Haag J; Krüger S; Simon E; Mathiak M; Ebert MP; Röcken C
Br J Cancer; 2013 Oct; 109(8):2217-27. PubMed ID: 24008668
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma.
Foroozan M; Roudi R; Abolhasani M; Gheytanchi E; Mehrazma M
Pathol Res Pract; 2017 Jun; 213(6):612-618. PubMed ID: 28552539
[TBL] [Abstract][Full Text] [Related]
17. Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer.
Khalvandi A; Abolhasani M; Madjd Z; Shekarabi M; Kourosh-Arami M; Mohsenzadegan M
APMIS; 2021 Jun; 129(6):291-303. PubMed ID: 33743542
[TBL] [Abstract][Full Text] [Related]
18. Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance.
Fong D; Steurer M; Obrist P; Barbieri V; Margreiter R; Amberger A; Laimer K; Gastl G; Tzankov A; Spizzo G
J Clin Pathol; 2008 Jan; 61(1):31-5. PubMed ID: 16775119
[TBL] [Abstract][Full Text] [Related]
19. Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer.
Schmidt M; Petry IB; Böhm D; Lebrecht A; von Törne C; Gebhard S; Gerhold-Ay A; Cotarelo C; Battista M; Schormann W; Freis E; Selinski S; Ickstadt K; Rahnenführer J; Sebastian M; Schuler M; Koelbl H; Gehrmann M; Hengstler JG
Breast Cancer Res Treat; 2011 Feb; 125(3):637-46. PubMed ID: 20352488
[TBL] [Abstract][Full Text] [Related]
20. [Expression of the epithelial cell adhesion molecule in prostate cancer and its clinical significance].
Li ZL; Jin RS
Zhonghua Nan Ke Xue; 2015 Apr; 21(4):320-4. PubMed ID: 26027098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]